Compare Bristol-Myers Squibb Co (BMY) vs Live Nation Entertainment, Inc. (LYV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Live Nation Entertainment, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $58.47 (market cap $116.30B), while Live Nation Entertainment, Inc. trades at $181.45 (market cap $42.25B). The key difference: Bristol-Myers Squibb Co is far larger — about 2.8× Live Nation Entertainment, Inc.'s market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Live Nation Entertainment, Inc. pays none. Which is the better fit depends on your goals.
| BMY | LYV | |
|---|---|---|
Market Cap | $116.30B | $42.25B |
Sector | Health | Industrials |
52-Week High | $62.37 | $186.59 |
52-Week Low | $42.60 | $125.61 |
Enterprise Value | $152.24B | $43.76B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Live Nation (LYV) trades at $183.25, up 1.92% with strong analyst support (88.6% buy ratings) and a $200.20 consensus target. The stock shows bullish technical signals with support at $178 and resistance at $185. Despite recent earnings misses, revenue grew to $25.2B in 2025, though net margins remain thin at 0.33% with negative ROE of -24.68%.
The outlook remains positive given strong concert demand and ticketing dominance, but elevated valuation (P/E 117.5) and regulatory scrutiny pose risks. Cash flow improved to $1.0B net in 2025, supporting growth investments. Institutional sentiment favors upside to price targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →
